An interventional study of Closed loop automated oxygen control in Infant, Premature and Airway Morbidity, sponsored by King's College Hospital NHS Trust. Recruiting at 1 site in United Kingdom. Open to participants aged 22 Weeks to 34 Weeks. Per ClinicalTrials.gov, last updated 2026-08-05.
Sponsored by King's College Hospital NHS Trust · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 100 studies in Premature Birth with a site in United Kingdom — 19 open to participants now, 25 under way, 1 of them phase 3. Premature Birth · United Kingdom.
Among the 100 studies in Premature Birth with a site in United Kingdom, this one is the 22nd largest by planned enrollment of the 54 interventional ones that give a count, is one of 3 that started in 2026, is one of 38 with no phase, reaches primary completion later than 20 of the 24 other live ones, and was the 99th registered.
2,557 studies on the registry are indexed under Premature Birth; 504 are open to participants now.
Browse Premature Birth studies →19 of the 100 studies in Premature Birth with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College Healthcare NHS Trust · Sites in United Kingdom
Ages 23 wk–30 wk
Imperial College London · Sites in United Kingdom
Ages up to 30 wk
South Tees Hospitals NHS Foundation Trust · Sites in United Kingdom
Ages 22 wk–32 wk
Queen Mary University of London · Sites in United Kingdom
Ages 18+ · Women only
University of Oxford · Sites in United Kingdom
Ages up to 37 wk
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 318 Premature Birth studies recruiting now, 88 (28%) set no upper age limit and 226 (71%) stop at 75 or younger; 243 take children under 18; 104 take healthy volunteers.
This study: 22 Weeks to 34 Weeks · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
100 studies; the count open now beside each. This study's row is marked.
First in 2000; this study’s year is marked. 3 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 76 is close to the median of 84 across 1,670 interventional studies indexed under Premature Birth.
Median enrollment 58 across the 54 interventional studies, 150 across the 46 observational. Of the 57 that completed or were terminated, 8 (14%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 100 have an industry lead sponsor. The 10 most frequent:
King's College Hospital NHS Trust is the lead sponsor of 171 studies on the registry; 56 are open to participants now.
King's College Hospital NHS Trust has 6 studies filed under Premature Birth — fewer than ten, so there is no comparison to draw.
11 of the studies in Premature Birth with a site in United Kingdom that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03168516Phase 3University Hospital TuebingenEffects of Closed-loop Automatic Control of FiO2 in Extremely Preterm Infants | 2026-12 |
| NCT04372953Murdoch Childrens Research InstitutePositive End-Expiratory Pressure (PEEP) Levels During Resuscitation of Preterm Infants at Birth (The POLAR Trial). | 2026-11-30 |
| NCT06705257South Tees Hospitals NHS Foundation TrustPEEP FOR LUNG RECRUITMENT IN PRETERM INFANTS-EIT STUDY | 2026-12-31 |
| NCT05306925University of LiverpoolAn Exploratory Study of Arginine Supplementation and the Postoperative Immune REsponse | 2026-12-31 |
| NCT06823115Indiana UniversityAssessment of Worldwide Acute Kidney Injury Epidemiology in Neonates 2.0 | 2027-01 |
Add all 11 to your calendar (.ics) → With an account.
Among the 100 studies in Premature Birth with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This randomised controlled trial aims to investigate the effectiveness of closed-loop automated oxygen control (CLAC) in preterm infants receiving non-invasive respiratory support and determine if it reduces the duration of supplementary oxygen treatment and improves achievement of oxygen saturation targets, reduces the incidences of hypoxia and hyperoxia, the number of manual adjustments to the inspired oxygen concentration (FiO2), and adverse outcomes including bronchopulmonary dysplasia (BPD).
The study will take place at King's College Hospital neonatal intensive care unit (NICU). Parents of preterm infants born at less than 34 weeks of gestation and receiving non-invasive respiratory support will be approached, informed and if appropriate consented to join the trial.
Participants will be randomised to receiving either automated or manual oxygen control.
The study will measure outcomes including the duration of supplementary oxygen treatment, the percentage of time spent within oxygen saturation targets, the incidences of hypoxia and hyperoxia, the number of manual FiO2 adjustments required, the overall duration of non-invasive respiratory support and length of neonatal unit stay, and the incidence of BPD at 36 weeks postmenstrual age (PMA). Results will be compared between the two groups.
Preterm infants frequently require supplemental oxygen to achieve adequate oxygen delivery to the tissues and allow for normal cell metabolism. Oxygen treatment, although life-saving, can further increase the risk of complications. Hyperoxia leads to the development of reactive oxide species (ROS) and increases oxidative stress for the neonates due to their immature antioxidant defence systems. Oxidative stress increases the risk of complications such as bronchopulmonary dysplasia and retinopathy of prematurity (ROP). On the other hand, hypoxia increases morbidity and mortality.
Studies have demonstrated that automated compared to manual oxygen control systems in preterm ventilated infants result in an improvement in the achievement of oxygen saturation targets, reduced time spent in hypoxia and hyperoxia and fewer manual adjustments to the inspired oxygen concentration. In addition, CLAC has been associated with earlier weaning of the inspired oxygen. In a RCT in preterm ventilated infants, CLAC was associated with shorter durations of mechanical ventilation (MV) and supplemental oxygen and reductions in the incidence of BPD and the proportion of infants discharged on home oxygen.
Preterm infants are increasingly managed on non-invasive respiratory support with an aim to minimise lung injury and reduce respiratory morbidity. Optimisation of supplemental oxygen treatment could further improve respiratory outcomes in this population. Previous studies on CLAC that included preterm infants on non invasive respiratory support showed promising results but they were of short duration. In addition, they did not report on the effect of CLAC on longer term outcomes. These limitations highlighted the need for an adequately powered randomised controlled trial (RCT) of CLAC versus manual oxygen control in preterm non-ventilated infants and for the whole duration of non-invasive respiratory support.
This study's hypothesis is that the use of CLAC in preterm infants \< 34 weeks of gestation receiving non-invasive respiratory support will reduce the duration of non-invasive ventilation (NIV). The investigators will also evaluate the time spent within oxygen saturation targets, the incidences of hypoxemia and hyperoxemia, the number of manual adjustments required by clinical staff, the total duration of supplemental oxygen treatment, the length of neonatal unit stay and the incidence of BPD at 36 weeks postmenstrual age (PMA).
This is a single centre, non-blinded, randomised controlled trial in preterm infants born at less than 34 weeks of gestation requiring non-invasive respiratory support at any postnatal age.
The investigators aim to recruit a minimum of 76 preterm infants (39 in each group) and over 12 months.
Informed written consent will be requested from the parents or legal guardians of the infants.
Eligible infants whose parents' consent to the study will be enrolled within 48 hours of initiation of non-invasive respiratory support. Infants who have not been eligible for recruitment within 48 hours of initiation of non-invasive support (for example outborn infants transferred to our unit at a later date) but who remain on it on day seven of life and beyond, they will be enrolled to the study immediately after obtaining parental consent and if less than fourteen days old.
Randomisation will be performed using an online randomisation generator. Patients will be receiving non-invasive support using SLE6000 ventilators or SLE6000N non-invasive respiratory device. Non-invasive support will include nasal continuous positive airway pressure (CPAP), non-invasive positive pressure ventilation (NIPPV) or humidified high flow nasal cannula oxygen (HHFNC). Settings will be manually adjusted by the clinical team as per unit's protocol. All participants will be connected to the standard bedside monitor (Philips IntelliVue MX750) that uses the Nellcor Neonatal SpO2 sensor. The intervention group, in addition to standard care will be also connected to the OxyGenie closed-loop oxygen saturation monitoring software (Inspiration Healthcare, Croydon, UK). Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
The nurse-to-patient ratio will be according to the unit's protocol that is determined on the patient's acuity.
Patients will be studied from enrolment until weaning of non-invasive ventilation or 36 weeks PMA or discharge. If an infant is weaned to low flow nasal cannula oxygen or room air and subsequently requires resuming non-invasive ventilation, they will be studied in their initial arm if less than 36 weeks PMA. Therefore, for those infants randomised at the intervention group CLAC will resume. Preterm infants that remain on non-invasive respiratory support beyond 36 weeks PMA will continue at their study arm (CLAC or manual oxygen control) till their first weaning attempt.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Preterm infants \<34 weeks of gestation and at any postnatal age on non-invasive respiratory support including:
Exclusion Criteria:
Automated oxygen titration
Device: Closed loop automated oxygen control
Manual oxygen titration
The OxyGenie closed-loop oxygen saturation monitoring software (Inspiration Healthcare) uses oxygen saturations from the SpO2 probe attached to the neonate, fed into an algorithm, to automatically adjust the percentage of inspired oxygen to maintain oxygen saturations within the target range. Manual adjustments including the percentage of FiO2 will be allowed at any point during the study if deemed appropriate by the clinical team.
The length of non-invasive ventilation
Number of days participant receives non-invasive ventilation
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the time spent within oxygen saturation targets
Percentage of time with oxygen saturation levels between 91-95%.
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the time spent in hypoxia (SpO2<80%)
Percentage of time with oxygen saturation levels below 80%
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the time spent in hyperoxia
Percentage of time with oxygen saturation levels above 98%.
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the number of manual adjustments required
Absolute difference in number of manual FiO2 adjustments
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the duration of supplemental oxygen treatment
Number of days infants received supplemental oxygen
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the length of neonatal unit stay
Number of days spent in neonatal unit
Time frame: Through study completion, up to 36 weeks post menstrual age
The change in the incidence of BPD at 36 weeks postmenstrual age
The number of diagnosed cases of BPD among participants
Time frame: Through study completion, up to 36 weeks post menstrual age
Plan to share: No
Started Jun 2026 (actual). Primary completion is estimated for Jun 2027, 12 months after the start.
Of 746 non-industry interventional studies with no phase under Premature Birth, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 47. This study's planned 12 months is below that.
Counting every sponsor, half of 764 studies reached it within 24 months; a quarter within 12 and three quarters within 47.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
King's College Hospital NHS Trust →